Abiopharma

🔍 CHAN KEVIN J (Executive)

Company: WORTHINGTON ENTERPRISES, INC. (WOR)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 1,030 shares of Common Shares (Direct)
  Date: 2026-06-25 | Code: A | equity_swap_involved: false | shares_owned_after: 6,836.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Shares (Direct)
  Date: 2026-06-25 | Code: H | nature_of_ownership: By 401(k) Plan | shares_owned_after: 3,061.32 | Footnotes: F2
• Acquired 4 shares of Phantom Stock (Derivative)
  Date: 2026-06-26 | Code: A | equity_swap_involved: false | shares_owned_after: 259.81 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: An award of restricted stock was granted pursuant to the Worthington Enterprises, Inc. 2024 Long-Term Incentive Plan. The restricted stock will vest on the third anniversary of the grant date.
• F2: The information in this report is based on a 401(k) Plan statement dated as of June 26, 2026.
• F3: The theoretical WOR common shares ("phantom stock") credited to the reporting person's account in the Worthington Industries, Inc. Amended and Restated 2005 Deferred Compensation Plan, as amended (the "Plan") track WOR common shares on a one-for-one basis.
• F4: Prior to October 1, 2014, the account balances related to the phantom stock investment option could be immediately transferred to other deemed investment options under the terms of the Plan. The Plan provides that, effective October 1, 2014 and thereafter, any amount credited in a participant's account to the phantom stock fund may not be transferred to an alternative deemed investment option under the Plan until distribution from the Plan. Distributions are made only in WOR common shares and generally commence upon leaving Worthington Enterprises, Inc. and its subsidiaries.